Subcellular Mislocalization of Mutant Hepatitis B X Proteins Contributes to Modulation of STAT/SOCS Signaling in Hepatocellular Carcinoma (original) (raw)
Article navigation
Research Articles| March 26 2009
aDepartment of Molecular Pathology, Institute of Pathology, University Hospital of Tuebingen, Tuebingen, Germany;
Search for other works by this author on:
aDepartment of Molecular Pathology, Institute of Pathology, University Hospital of Tuebingen, Tuebingen, Germany;
bDepartment of Pathophysiology, Vietnam Military Medical University, Hadong City, and
Search for other works by this author on:
aDepartment of Molecular Pathology, Institute of Pathology, University Hospital of Tuebingen, Tuebingen, Germany;
Search for other works by this author on:
cDepartment of Infectious Diseases, Tran Hung Dao Hospital, Hanoi, Vietnam;
Search for other works by this author on:
dDepartment of Medicine, Victorian Infectious Diseases Service, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Vic., Australia;
Search for other works by this author on:
eGerman Cancer Research Center, Applied Tumor Virology, Heidelberg, Germany
Search for other works by this author on:
aDepartment of Molecular Pathology, Institute of Pathology, University Hospital of Tuebingen, Tuebingen, Germany;
Search for other works by this author on:
dDepartment of Medicine, Victorian Infectious Diseases Service, Royal Melbourne Hospital, The University of Melbourne, Melbourne, Vic., Australia;
Search for other works by this author on:
Intervirology (2009) 51 (6): 432–443.
Received:
September 18 2008
Published Online:
March 26 2009
Accepted:
November 02 2009
Abstract
Objective: The hepatitis B virus X (HBx) protein plays an important role in the pathogenesis of hepatocellular carcinoma (HCC). One potential mechanism by which HBx can cause liver cancer may involve intracellular distribution and consecutively modulation of the proliferative important STAT/SOCS signaling with upregulation of STAT3. Methods: 153 Vietnamese HBV-infected patients, including 48 patients with HCC, were analyzed. HBx sequences were determined by sequencing and subcloned for functional experiments. Intracellular localization of HBx mutants was determined by immunofluorescence assays. The impact of HBx mutants on JAK/STAT/SOCS signaling was investigated using Western blot and PCR analyses. Results: In 4/48 HCC patients, truncated HBx together with full-length mutated HBx proteins were observed. Expression of HBx mutant proteins demonstrated an atypical nuclear and perinuclear localization. Functional experiments to determine the effect of HBx mutants on STAT/SOCS signaling demonstrated a significantly increased upregulation of STAT3 activation (p > 0.001) in comparison to wild-type (wt)-HBx. STAT1 was not activated either by wt-HBx or HBx mutants. Interestingly, SOCS1 and SOCS3 expression was not activated by wt-HBx and HBx mutants. Conclusions: Our results suggest that atypical nuclear/perinuclear localization of HBx mutants might be responsible for an enhanced activation of STAT3, inhibition of STAT1 and silencing of SOCS1/SOCS3 expression. This observation points to an active role of HBx mutants in hepatocarcinogenesis that involves dysregulation of STAT/SOCS signaling.
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$45.00
1 Karger Article Bundle Token
$170
Rental
This article is also available for rental through DeepDyve. 